Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Carcinoma, Merkel Cell × lanreotide × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Neuroendocrine Tumors 12 Carcinoid Tumor 5 Acromegaly 3 Serotonin Syndrome 2 Pituitary Neoplasms 2 Gastro-enteropancreatic neuroendocrine tumor 2 Carcinoma, Hepatocellular 2 Prostatic Neoplasms 1 Pheochromocytoma 1 Peritoneal Neoplasms 1 Paraganglioma 1 Pancreatic Neoplasms 1 Neuroendocrine Tumour With Carcinoid Symptoms 1 Neuroendocrine Tumors in Lung 1 Neoplastic Cells, Circulating 1 Neoplasms 1 Neoplasm Metastasis 1 Intestinal Obstruction 1 Growth Hormone-Secreting Pituitary Adenoma 1 Gigantism 1 Gastrointestinal Neoplasms 1 Flushing 1 Endocrine Tumors 1 Diarrhea 1 Carcinoma, Merkel Cell 1 Carcinoma 1 Carcinoid Heart Disease 1 Adenoma, Islet Cell 1

Interventions

pembrolizumab 24 avelumab 19 Nivolumab 18 Ipilimumab 9 Radiotherapy 8 Cyclophosphamide 8 atezolizumab 7 fludarabine 6 cemiplimab 5 aldesleukin 5 Radiation 5 talimogene laherparepvec 4 durvalumab 4 Specimen Handling 4 Interleukin-2 4 Biopsy 4 ALT-803 4 poly ICLC 3 Radiosurgery 3 Magnetic Resonance Spectroscopy 3 Bevacizumab 3 lutetium Lu 177 dotatate 2 fludarabine phosphate 2 domatinostat 2 budigalimab 2 Sirolimus 2 Paclitaxel 2 Interferon-beta 2 Immunoglobulin G 2 Immune Checkpoint Inhibitors 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02351128 2017-10-18

PHRC-Merkel

University Hospital, Grenoble

Phase 2 Completed

Carcinoma, Merkel Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡